We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 59% below its sector, cheaper than its peers on earnings.
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 1707.TW and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
